Recent Updates
Recently added Catalysts
SNTI Positive Sentiment

Correlative data from an ongoing Phase 1, multicenter study of SENTI-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action

Monday, December 8, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The ongoing Phase 1 study of SENTI-202, a novel CAR NK cell therapy for Acute Myeloid Leukemia (AML), presents correlative data that aligns with its clinical efficacy. This first-in-class therapy targets CD33 and/or FLT3 while avoiding endomucin. The findings were shared at the American Society of Hematology Annual Meeting 2025.
Price reaction · baseline $2.13 (2025-12-05 close) · hit pre-market · 3 other SNTI headline(s) in the window, move may be shared
day 0 close
+12.2%
day 1
-27.7%
day 3 · peak
-33.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • SENTI-202 shows promising clinical activity.
  • The therapy utilizes a unique mechanism of action.
  • The study is multicenter, indicating broad collaboration.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
76.7%
average across 4 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
SENTI-202
Phase 1 · AML/MDS

Full Press Release Details

American Society of Hematology (ASH) Annual Meeting 2025 Muharrem Muftuoglu, Enping Hong, Nosha Farhadfar, Stephen A. Strickland, Ashish R. Bajel, Alireza Eghtedar, Gary Schiller, Mahesh Basyal, Li Li, Lawrence Naitmazi, Rochelle Emery, Timothy Lu, Brian S. Garrison, Kanya Rajangam, Farhad Ravandi, Michael Andreeff

Frequently Asked Questions

What is SENTI-202?

SENTI-202 is a first-in-class CAR NK cell therapy targeting CD33 and/or FLT3 for AML.

What type of study is being conducted for SENTI-202?

A Phase 1 multicenter study is currently underway for SENTI-202.

Where was the data for SENTI-202 presented?

The data was presented at the American Society of Hematology Annual Meeting 2025.

What is the mechanism of action for SENTI-202?

SENTI-202 employs a unique logic gated mechanism of action in treating AML.

ShareAdd on Google
Tags: SNTI Viatris Investor Conferences Healthcare SENTI-202 Acute Myeloid Leukemia CAR NK cell therapy clinical study
Last updated: Dec 8, 2025

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~5 mo
High dilution risk
Lead asset
SENTI-202Phase 1
AML/MDS →

Catalyst track record

+84%
best trade around SNTI's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SNTI.

See every catalyst's timing & PoA →